Caribou Biosciences (CRBU) Net Margin (2020 - 2025)
Caribou Biosciences (CRBU) has disclosed Net Margin for 6 consecutive years, with 1337.58% as the latest value for Q3 2025.
- On a quarterly basis, Net Margin rose 55165.0% to 1337.58% in Q3 2025 year-over-year; TTM through Dec 2025 was 1066.47%, a 60069.0% increase, with the full-year FY2024 number at 1491.95%, down 119589.0% from a year prior.
- Net Margin was 1337.58% for Q3 2025 at Caribou Biosciences, up from 1783.95% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 61.84% in Q3 2023 to a low of 1893.87% in Q1 2024.
- A 5-year average of 1058.42% and a median of 881.92% in 2023 define the central range for Net Margin.
- Peak YoY movement for Net Margin: soared 77209bps in 2021, then tumbled -182739bps in 2024.
- Caribou Biosciences' Net Margin stood at 722.12% in 2021, then decreased by -15bps to 828.22% in 2022, then decreased by -27bps to 1052.33% in 2023, then tumbled by -78bps to 1871.69% in 2024, then increased by 29bps to 1337.58% in 2025.
- Per Business Quant, the three most recent readings for CRBU's Net Margin are 1337.58% (Q3 2025), 1783.95% (Q2 2025), and 1871.69% (Q4 2024).